GOG-0218 & ICON7 (bevacizumab)
Adding the blood-vessel blocker bevacizumab to first-line chemotherapy delayed relapse by a few months but did not extend life overall.
GOG-0218 (1,873 patients): PFS 14.1 vs 10.3 months with concurrent-plus-maintenance bevacizumab (HR 0.72); no OS benefit (NEJM 2011). ICON7 (1,528): modest PFS gain, with an OS benefit confined to high-risk (stage IV or suboptimally debulked) disease. Bevacizumab became a first-line option, mainly for high-risk patients and as the partner for olaparib in PAOLA-1.
- Median 14.1 vs 10.3 months with Bevacizumab throughout compared with Chemotherapy alone; about 3.8 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 28 percent lower chance of the event at any given time (hazard ratio 0.72, likely range 0.63 to 0.82).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Newly diagnosed advanced ovarian cancer: carboplatin-paclitaxel ± bevacizumab with bevacizumab maintenance. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
3,401 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (GOG-0218)primary | Bevacizumab throughout | — | 14.1 months | 0.72 (0.63–0.82) | — | link |
| Chemotherapy alone | — | 10.3 months |
Pages like this
not linked directly; found by shared links- TrialPAOLA-1 / ENGOT-ov25
Shares ARCAGY-GINECO, Bevacizumab, VEGF / VEGFR, Ovarian cancer.
- TrialOUTBACK / ANZGOG 0902 / GOG-0274
Shares GOG Foundation, Paclitaxel / nab-paclitaxel, Carboplatin.
- TrialBEATcc / ENGOT-Cx10 / GOG-3030
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, VEGF / VEGFR.
- TrialRUBY / ENGOT-EN6 / GOG-3031
Shares GOG Foundation, Paclitaxel / nab-paclitaxel, Carboplatin.
- PairingPARP inhibitor + bevacizumab maintenance (HRD-positive)
Shares Bevacizumab, VEGF / VEGFR, Ovarian cancer.
- TrialKEYNOTE-B96 / ENGOT-ov65
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, Ovarian cancer.
- TrialNRG-GY018 / KEYNOTE-868
Shares GOG Foundation, Paclitaxel / nab-paclitaxel, Carboplatin.
- IdeaA strategic reserve of essential generic cancer drugs to end recurring shortages
Shares Paclitaxel / nab-paclitaxel, Carboplatin.